title: Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital.
abstract: Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLPE) were isolated from clinical specimens from 130 to 140 patients/year in 1989-1991 in our hospital. In February 1992, a control program was initiated: screening tests in 3 intensive care units (ICUs) and contact-isolation precautions in all units. The septic surgical unit served as an isolation ward for surgical patients from whom ESBLPE was isolated. In 1992, the incidence of ESBLPE acquisition failed to decrease, and most acquisitions occurred in 3 ICUs. Critical evaluation of implementation of isolation procedures in these ICUs prompted corrective measures for barrier precautions. The incidence of acquired cases subsequently decreased, and a second evaluation determined that these measures had been correctly applied. The incidence of acquired cases in the septic surgical unit was lower than those in the other units. Decreases were also found in the incidence of acquisition of other hand-transmitted multidrug-resistant organisms. Barrier precautions, screening tests for ICU patients, and grouping of cohorts after ICU discharge are effective in controlling the spread of multidrug-resistant microorganisms by cross-contamination. The outbreak was effectively controlled without restricting antimicrobial use.
authors.affiliation: Unité d'Hygiène et de Lutte contre l'Infection Nosocomiale, Group Hospitalier Bichat-Claude Bernard, Paris, France. jean-christophe. lucet@bch.ap-hop-paris.fr
authors.forename: J C
authors.initials: JC
authors.lastname: Lucet
authors.forename: D
authors.initials: D
authors.lastname: Decré
authors.forename: A
authors.initials: A
authors.lastname: Fichelle
authors.forename: M L
authors.initials: ML
authors.lastname: Joly-Guillou
authors.forename: M
authors.initials: M
authors.lastname: Pernet
authors.forename: C
authors.initials: C
authors.lastname: Deblangy
authors.forename: M J
authors.initials: MJ
authors.lastname: Kosmann
authors.forename: B
authors.initials: B
authors.lastname: Régnier
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D004196:Disease Outbreaks; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification*; D004756:Enterobacteriaceae Infections / Q000453:epidemiology / Q000517:prevention & control*; D006785:Hospitals, University / Q000706:statistics & numerical data*; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D017053:Infection Control; D007362:Intensive Care Units / Q000706:statistics & numerical data; D010297:Paris / Q000453:epidemiology; D001618:beta-Lactamases / Q000096:biosynthesis*
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D015378:Imipenem; D001618:beta-Lactamases